Why LB Pharmaceuticals Inc’s (LBRX) Stock Is Up 5.36%
As of Tuesday, August 04, LB Pharmaceuticals Inc’s LBRX share price has surged by 5.36%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
Commentary & Analysis
Why LB Pharmaceuticals Inc’s (LBRX) Stock Is Up 5.78%
As of Monday, August 03, LB Pharmaceuticals Inc’s LBRX share price has surged by 5.78%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why LB Pharmaceuticals Inc’s (LBRX) Stock Is Up 7.76%
As of Wednesday, July 29, LB Pharmaceuticals Inc’s LBRX share price has surged by 7.76%, which has investors questioning if this is right time to sell.Michael Rose
Why LB Pharmaceuticals Inc’s (LBRX) Stock Is Up 9.41%
As of Wednesday, July 22, LB Pharmaceuticals Inc’s LBRX share price has surged by 9.41%, which has investors questioning if this is right time to sell.Michael Rose
Why LB Pharmaceuticals Inc’s (LBRX) Stock Is Up 8.37%
As of Wednesday, June 17, LB Pharmaceuticals Inc’s LBRX share price has surged by 8.37%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | LBRX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,492.0 | $626.3 | 50% |
|
| Shares Out (Mil) | 30.1 | 43.4 | 37% |
|
| Institutional Ownership | 99.1% | 83.9% | 85% |
|
| Float (Mil) | 26.5 | 45.7 | 33% |
|
| Beta | na | 0.73 | na |
|
| Avg Daily Volume (000s) | 275 | 309 | 50% |
|
| Price Change (52-week) |
na | 66.6% | na |
|
| Growth | LBRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | na | (1.6%) | na |
|
| EPS (5yr) | na | 15.1% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.0%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 6 | 7 | |
| Current EPS | ($1.564) | ($5.542) | ($5.036) | |
| Month Ago EPS | ($0.927) | ($3.337) | ($4.184) | |
| # Rev Up | 2 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.948) | ($3.512) | ($4.490) | |
| Year/Year Chg | (8.6%) | 76.9% | 68.5% | |
| Financials | LBRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $317 | na |
|
| Net Income (TTM) (Mil) | ($86) | ($11) | 12% |
|
| EPS (TTM) | ($3.814) | ($0.700) | 9% |
|
| Operating Cash Flow (TTM) (Mil) | ($82) | ($6) | 7% |
|
| Net Cash Flow (TTM) (Mil) | $269 | $6 | 86% |
|
| Long-Term Debt (Q1) (Mil) | $4 | $6 | 24% |
|
| Enterprise Value (Q1) (Mil) | $1,233 | $525 | 43% |
|
| Valuation | LBRX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.99 | 2.69 | 73% |
|
| P/E | na | 16.8 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | LBRX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 68.8% | na |
|
| Net Margin | na | (1.4%) | na |
|
| ROA | (45.0%) | (24.1%) | 13% |
|
| ROE | (75.0%) | (21.4%) | 12% |
|
| Liabilities to Assets | 8.1% | 33.1% | 5% |
|
| F-Score | 2 | 3 | 7% |
|
Passing Stock Screens
As of 9/10/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Est Rev: Lowest 30 Down
Factors: Earnings Estimates
Introduction to the use of earnings estimates.
| Performance Since Inception: | 3.3% |
| +/- S&P 500: | -4.2 |
FACTOR STRATEGY
Est Rev: Down 5% Screen
Factors: Earnings Estimates
Introduction to the use of earnings estimates.
| Performance Since Inception: | 2.8% |
| +/- S&P 500: | -4.7 |
